MEK in cancer and cancer therapy

Pharmacology and Therapeutics

Volumn 141, Issue 2, 2014, Pages 160-171

  Neuzillet, Cindy ^a   Tijeras Raballand, Annemilaï ^b   De Mestier, Louis ^a   Cros, Jérôme ^a   Faivre, Sandrine ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b AAREC Filia Research   (France)

Author keywords

Combination; ERK inhibitors; MAP kinases; Predictive biomarker; Resistance; Targeted therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ARRY 438162; BAY 86 9766; COBIMETINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PIMASERTIB; RAS PROTEIN; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG;

ASTHENIA; BASAL LIKE BREAST CANCER; BLURRED VISION; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DIARRHEA; DRUG MECHANISM; EYE TOXICITY; HUMAN; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA AND VOMITING; PANCREAS CANCER; PRIORITY JOURNAL; RASH; RETINA HEMORRHAGE; RETINA VEIN OCCLUSION; REVIEW; SIGNAL TRANSDUCTION; UVEA MELANOMA;

COLORECTAL CANCER; COMBINATION; CRC; EMT; EPITHELIAL-TO-MESENCHYMAL TRANSITION; ERK; ERK INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED KINASE; GAP; GEF; GTPASE-ACTIVATING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HAZARD RATIO; HCC; HEPATOCELLULAR CARCINOMA; HR; MAP KINASE; MAP KINASES; MAPK; MEK; MEK INHIBITOR; MEKI; MITOGEN-ACTIVATED EXTRACELLULAR SIGNAL-REGULATED KINASE; NON-SMALL CELL LUNG CARCINOMA; NSCLC; PAC; PANCREATIC ADENOCARCINOMA; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PANIN; PFS; PRB; PREDICTIVE BIOMARKER; PROGRESSION-FREE SURVIVAL; RESISTANCE; RETINOBLASTOMA PROTEIN; TARGETED THERAPY; TKR; TYROSINE KINASE RECEPTOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; NEOPLASMS; PROTEIN KINASE INHIBITORS; RAS PROTEINS;

EID: 84891851458     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.10.001     Document Type: Review

References (130)

1. E.V. Abel, K.J. Basile, C.H. Kugel III, A.K. Witkiewicz, K. Le, and R.K. Amaravadi et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 J Clin Invest 123 2013 2155 2168
2. L.A. Allan, N. Morrice, S. Brady, G. Magee, S. Pathak, and P.R. Clarke Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK Nat Cell Biol 5 2003 647 654
3. G. Ambrosini, C.A. Pratilas, L.X. Qin, M. Tadi, O. Surriga, and R.D. Carvajal et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance Clin Cancer Res 18 2012 3552 3561
4. P.A. Ascierto, D. Schadendorf, C. Berking, S.S. Agarwala, C.M. van Herpen, and P. Queirolo et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Lancet Oncol 14 2013 249 256
5. B.A. Ballif, and J. Blenis Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals Cell Growth Differ 12 2001 397 408
6. K. Balmanno, S.D. Chell, A.S. Gillings, S. Hayat, and S.J. Cook Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines Int J Cancer 125 2009 2332 2341
7. K. Balmanno, and S.J. Cook Tumour cell survival signalling by the ERK1/2 pathway Cell Growth Differ 16 2009 368 377
8. A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
9. A.R. Baudy, T. Dogan, J.E. Flores-Mercado, K.P. Hoeflich, F. Su, and N. van Bruggen et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973 EJNMMI Res 2 2012 22
10. T. Bekaii-Saab, M.A. Phelps, X. Li, M. Saji, L. Goff, and J.S. Kauh et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers J Clin Oncol 29 2011 2357 2363
11. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
12. G. Bodoky, C. Timcheva, D.R. Spigel, P.J. La Stella, T.E. Ciuleanu, and G. Pover et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest New Drugs 30 2012 1216 1223
13. C.D. Britten PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types Cancer Chemother Pharmacol 71 2013 1395 1409
14. K. Burkhard, S. Smith, R. Deshmukh, A.D. MacKerell Jr., and P. Shapiro Development of extracellular signal-regulated kinase inhibitors Curr Top Med Chem 9 2009 678 689
15. D.F. Calvisi, S. Ladu, A. Gorden, M. Farina, E.A. Conner, and J.S. Lee et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 2006 1117 1128
16. C.E. Cano, Y. Motoo, and J.L. Iovanna Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma Sci World J 10 2010 1947 1957
17. F. Catalanotti, D.B. Solit, M.P. Pulitzer, M.F. Berger, S.N. Scott, and T. Iyriboz et al. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma Clin Cancer Res 19 2013 2257 2264
18. Q. Chang, M.S. Chapman, J.N. Miner, and D.W. Hedley Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts BMC Cancer 10 2010 515
19. Q. Chang, E. Chen, and D.W. Hedley Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models Cancer Biol Ther 8 2009 1893 1901
20. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
21. W.H. Chappell, L.S. Steelman, J.M. Long, R.C. Kempf, S.L. Abrams, and R.A. Franklin et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health Oncotarget 2 2011 135 164
22. T.C. Chen, Y.Y. Jan, and T.S. Yeh K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy Ann Surg Oncol 19 Suppl. 3 2012 S675 S681
23. L. Chen, Y. Shi, C.Y. Jiang, L.X. Wei, Y.L. Wang, and G.H. Dai Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma Eur J Surg Oncol 37 2011 513 520
24. Y. Cheng, G. Zhang, and G. Li Targeting MAPK pathway in melanoma therapy Cancer Metastasis Rev 2013 Apr 13. [Epub ahead of print]
25. L.C. Coles, and P.E. Shaw PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway Oncogene 21 2002 2236 2244
26. R.B. Corcoran, D. Dias-Santagata, K. Bergethon, A.J. Iafrate, J. Settleman, and J.A. Engelman BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation Sci Signal 3 2010 ra84
27. R.B. Corcoran, J. Settleman, and J.A. Engelman Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers Oncotarget 2 2011 336 346
28. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
29. A. De Luca, M.R. Maiello, A. D'Alessio, M. Pergameno, and N. Normanno The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches Expert Opin Ther Targets 16 Suppl. 2 2012 S17 S27
30. A.S. Dhillon, S. Hagan, O. Rath, and W. Kolch MAP kinase signalling pathways in cancer Oncogene 26 2007 3279 3290
31. J.R. Dry, S. Pavey, C.A. Pratilas, C. Harbron, S. Runswick, and D. Hodgson et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) Cancer Res 70 2010 2264 2273
32. J.S. Duncan, M.C. Whittle, K. Nakamura, A.N. Abell, A.A. Midland, and J.S. Zawistowski et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer Cell 149 2012 307 321
33. J. Edeline, E. Boucher, Y. Rolland, E. Vauleon, M. Pracht, and C. Perrin et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma Cancer 118 2012 147 156
34. C.M. Emery, K.G. Vijayendran, M.C. Zipser, A.M. Sawyer, L. Niu, and J.J. Kim et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc Natl Acad Sci U S A 106 2009 20411 20416
35. J.A. Engelman, and J. Settleman Acquired resistance to tyrosine kinase inhibitors during cancer therapy Curr Opin Genet Dev 18 2008 73 79
36. European Association for the Study of the, L., European Organisation for, R., & Treatment of, C EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
37. S. Faivre, M. Zappa, V. Vilgrain, E. Boucher, J.Y. Douillard, and H.Y. Lim et al. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib Clin Cancer Res 17 2011 4504 4512
38. L. Fattore, E. Marra, M.E. Pisanu, A. Noto, C. de Vitis, and F. Belleudi et al. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies J Transl Med 11 2013 180
39. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
40. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, and M. Milhem et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
41. T. Furukawa, M. Sunamura, F. Motoi, S. Matsuno, and A. Horii Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer Am J Pathol 162 2003 1807 1815
42. A.K. Ganti Epidermal growth factor receptor signaling in nonsmall cell lung cancer Cancer Invest 28 2010 515 525
43. E.B. Garon, R.S. Finn, W. Hosmer, J. Dering, C. Ginther, and S. Adhami et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines Mol Cancer Ther 9 2010 1985 1994
44. S. Giambartolomei, F. Covone, M. Levrero, and C. Balsano Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein Oncogene 20 2001 2606 2610
45. S. Gysin, S.H. Lee, N.M. Dean, and M. McMahon Pharmacologic inhibition of RAF → MEK → ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1 Cancer Res 65 2005 4870 4880
46. J.D. Hainsworth, C.L. Cebotaru, V. Kanarev, T.E. Ciuleanu, D. Damyanov, and P. Stella et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens J Thorac Oncol 5 2010 1630 1636
47. E. Halilovic, Q.B. She, Q. Ye, R. Pagliarini, W.R. Sellers, and D.B. Solit et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling Cancer Res 70 2010 6804 6814
48. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
49. G. Hatzivassiliou, B. Liu, C. O'Brien, J.M. Spoerke, K.P. Hoeflich, and P.M. Haverty et al. ERK inhibition overcomes acquired resistance to MEK inhibitors Mol Cancer Ther 11 2012 1143 1154
50. E.B. Haura, A.D. Ricart, T.G. Larson, P.J. Stella, L. Bazhenova, and V.A. Miller et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 16 2010 2450 2457
51. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
52. J. Hayashi, H. Aoki, K. Kajino, M. Moriyama, Y. Arakawa, and O. Hino Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha Hepatology 32 2000 958 961
53. A.F. Hezel, A.C. Kimmelman, B.Z. Stanger, N. Bardeesy, and R.A. Depinho Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev 20 2006 1218 1249
54. S.R. Hingorani, E.F. Petricoin, A. Maitra, V. Rajapakse, C. King, and M.A. Jacobetz et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
55. K.P. Hoeflich, M. Merchant, C. Orr, J. Chan, D. Den Otter, and L. Berry et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition Cancer Res 72 2012 210 219
56. K.P. Hoeflich, C. O'Brien, Z. Boyd, G. Cavet, S. Guerrero, and K. Jung et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models Clin Cancer Res 15 2009 4649 4664
57. S.V. Holt, A. Logie, B.R. Davies, D. Alferez, S. Runswick, and S. Fenton et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055) Cancer Res 72 2012 1804 1813
58. S.V. Holt, A. Logie, R. Odedra, A. Heier, S.P. Heaton, and D. Alferez et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models Br J Cancer 106 2012 858 866
59. W. Huang, A.H. Yang, D. Matsumoto, W. Collette, L. Marroquin, and M. Ko et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion J Ocul Pharmacol Ther 25 2009 519 530
60. H. Huynh, T.T. Nguyen, K.H. Chow, P.H. Tan, K.C. Soo, and E. Tran Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis BMC Gastroenterol 3 2003 19
61. N. Ishimura, K. Yamasawa, M.A. Karim Rumi, Y. Kadowaki, S. Ishihara, and Y. Amano et al. BRAF and K-ras gene mutations in human pancreatic cancers Cancer Lett 199 2003 169 173
62. Y. Ito, Y. Sasaki, M. Horimoto, S. Wada, Y. Tanaka, and A. Kasahara et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma Hepatology 27 1998 951 958
63. F. Janku, D.J. Stewart, and R. Kurzrock Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol 7 2010 401 414
64. P.A. Janne, A.T. Shaw, J.R. Pereira, G. Jeannin, J. Vansteenkiste, and C. Barrios et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 2013 38 47
65. J. Jing, J. Greshock, J.D. Holbrook, A. Gilmartin, X. Zhang, and E. McNeil et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212 Mol Cancer Ther 11 2012 720 729
66. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, and L.A. Johnson et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
67. B. Jovanovic, S. Egyhazi, M. Eskandarpour, P. Ghiorzo, J.M. Palmer, and G. Bianchi Scarra et al. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations J Invest Dermatol 130 2010 618 620
68. E.K. Kim, and E.J. Choi Pathological roles of MAPK signaling pathways in human diseases Biochim Biophys Acta 1802 2010 396 405
69. K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, and J.A. Sosman et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol 31 2013 482 489
70. J.M. Kirkwood, L. Bastholt, C. Robert, J. Sosman, J. Larkin, and P. Hersey et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma Clin Cancer Res 18 2012 555 567
71. A.S. Little, K. Balmanno, M.J. Sale, S. Newman, J.R. Dry, and M. Hampson et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells Sci Signal 4 2011 ra17
72. A.S. Little, K. Balmanno, M.J. Sale, P.D. Smith, and S.J. Cook Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling Biochem Soc Trans 40 2012 73 78
73. A. Loboda, M. Nebozhyn, R. Klinghoffer, J. Frazier, M. Chastain, and W. Arthur et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors BMC Med Genet 3 2010 26
74. P.M. Lorusso, A.A. Adjei, M. Varterasian, S. Gadgeel, J. Reid, and D.Y. Mitchell et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies J Clin Oncol 23 2005 5281 5293
75. P.M. LoRusso, S.S. Krishnamurthi, J.J. Rinehart, L.M. Nabell, L. Malburg, and P.B. Chapman et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 2010 1924 1937
76. G. Luo, J. Long, L. Qiu, C. Liu, J. Xu, and X. Yu Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis Pancreatology 11 2011 595 600
77. J. Luo, N.L. Solimini, and S.J. Elledge Principles of cancer therapy: oncogene and non-oncogene addiction Cell 136 2009 823 837
78. V. Martin, F. Botta, E. Zanellato, F. Molinari, S. Crippa, and L. Mazzucchelli et al. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features Histol Histopathol 27 2012 785 792
79. G. Maurer, B. Tarkowski, and M. Baccarini Raf kinases in cancer-roles and therapeutic opportunities Oncogene 30 2011 3477 3488
80. J.A. McCubrey, L.S. Steelman, S.L. Abrams, W.H. Chappell, S. Russo, and R. Ove et al. Emerging MEK inhibitors Expert Opin Emerg Drugs 15 2010 203 223
81. J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, and F. Chang et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim Biophys Acta 1773 2007 1263 1284
82. E.T. McKinley, R.A. Smith, P. Zhao, A. Fu, S.A. Saleh, and M.I. Uddin et al. 3′-Deoxy-3′-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer J Nucl Med 54 2013 424 430
83. A.M. Mirza, S. Gysin, N. Malek, K. Nakayama, J.M. Roberts, and M. McMahon Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT Mol Cell Biol 24 2004 10868 10881
84. O.K. Mirzoeva, D. Das, L.M. Heiser, S. Bhattacharya, D. Siwak, and R. Gendelman et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition Cancer Res 69 2009 565 572
85. C. Montagut, and J. Settleman Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Lett 283 2009 125 134
86. C. Montero-Conde, S. Ruiz-Llorente, J.M. Dominguez, J.A. Knauf, A. Viale, and E.J. Sherman et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas Cancer Discov 3 2013 520 533
87. E.J. Morris, S. Jha, C.R. Restaino, P. Dayananth, H. Zhu, and A. Cooper et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors Cancer Discov 3 2013 742 750
88. J.P. Morris 4th, S.C. Wang, and M. Hebrok KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma Nat Rev Cancer 10 2010 683 695
89. L.O. Murphy, M.W. Cluck, S. Lovas, F. Otvos, R.F. Murphy, and A.V. Schally et al. Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions Br J Cancer 84 2001 926 935
90. N.F. Neel, T.D. Martin, J.K. Stratford, T.P. Zand, D.J. Reiner, and C.J. Der The RalGEF-Ral effector signaling network: the road less traveled for anti-Ras drug discovery Genes Cancer 2 2011 275 287
91. C. Neuzillet, P. Hammel, A. Tijeras-Raballand, A. Couvelard, and E. Raymond Targeting the Ras-ERK pathway in pancreatic adenocarcinoma Cancer Metastasis Rev 32 2013 147 162
92. S.I. Nikolaev, D. Rimoldi, C. Iseli, A. Valsesia, D. Robyr, and C. Gehrig et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma Nat Genet 44 2012 133 139
93. B.H. O'Neil, L.W. Goff, J.S. Kauh, J.R. Strosberg, T.S. Bekaii-Saab, and R.M. Lee et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma J Clin Oncol 29 2011 2350 2356
94. M.D. Onken, L.A. Worley, M.D. Long, S. Duan, M.L. Council, and A.M. Bowcock et al. Oncogenic mutations in GNAQ occur early in uveal melanoma Invest Ophthalmol Vis Sci 49 2008 5230 5234
95. J. Qin, H. Xin, and B.J. Nickoloff Specifically targeting ERK1 or ERK2 kills melanoma cells J Transl Med 10 2012 15
96. K. Rajalingam, R. Schreck, U.R. Rapp, and S. Albert Ras oncogenes and their downstream targets Biochim Biophys Acta 1773 2007 1177 1195
97. J.W. Ramos The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells Int J Biochem Cell Biol 40 2008 2707 2719
98. A.D. Rhim, and B.Z. Stanger Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways Prog Mol Biol Transl Sci 97 2010 41 78
99. J. Rinehart, A.A. Adjei, P.M. Lorusso, D. Waterhouse, J.R. Hecht, and R.B. Natale et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J Clin Oncol 22 2004 4456 4462
100. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
101. K. Roovers, and R.K. Assoian Integrating the MAP kinase signal into the G1 phase cell cycle machinery Bioessays 22 2000 818 826
102. G. Safaee Ardekani, S.M. Jafarnejad, L. Tan, A. Saeedi, and G. Li The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis PLoS One 7 2012 e47054
103. R.P. Sahu, S. Batra, P.K. Kandala, T.L. Brown, and S.K. Srivastava The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines Cancer Chemother Pharmacol 67 2011 481 487
104. L. Santarpia, S.M. Lippman, and A.K. El-Naggar Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy Expert Opin Ther Targets 16 2012 103 119
105. R. Schafer, and C. Sers RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function Adv Enzym Regul 51 2011 126 136
106. C.M. Schmidt, I.H. McKillop, P.A. Cahill, and J.V. Sitzmann Increased MAPK expression and activity in primary human hepatocellular carcinoma Biochem Biophys Res Commun 236 1997 54 58
107. K.J. Schmitz, J. Wohlschlaeger, H. Lang, G.C. Sotiropoulos, M. Malago, and K. Steveling et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection J Hepatol 48 2008 83 90
108. J.S. Sebolt-Leopold, and R. Herrera Targeting the mitogen-activated protein kinase cascade to treat cancer Nat Rev Cancer 4 2004 937 947
109. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, and A. Basso et al. BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
110. M.L. Sos, S. Fischer, R. Ullrich, M. Peifer, J.M. Heuckmann, and M. Koker et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer Proc Natl Acad Sci U S A 106 2009 18351 18356
111. J.P. Spano, C. Lagorce, D. Atlan, G. Milano, J. Domont, and R. Benamouzig et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol 16 2005 102 108
112. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, and O. Spleiss et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
113. R.J. Sullivan, and K.T. Flaherty Resistance to BRAF-targeted therapy in melanoma Eur J Cancer 49 2013 1297 1304
114. X. Tan, H. Egami, M. Abe, F. Nozawa, M. Hirota, and M. Ogawa Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway J Clin Pathol 58 2005 1242 1248
115. X. Tan, Y. Tamori, H. Egami, S. Ishikawa, T. Kurizaki, and E. Takai et al. Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation Oncol Rep 11 2004 993 998
116. A. Tannapfel, F. Sommerer, M. Benicke, A. Katalinic, D. Uhlmann, and H. Witzigmann et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 52 2003 706 712
117. A. Tijeras-Raballand, C. Neuzillet, A. Couvelard, M. Serova, A. de Gramont, and P. Hammel et al. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies Target Oncol 7 2012 173 181
118. J.I. Trujillo MEK inhibitors: a patent review 2008-2010 Expert Opin Ther Pat 21 2011 1045 1069
119. S. Ueda, S. Ogata, H. Tsuda, N. Kawarabayashi, M. Kimura, and Y. Sugiura et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 29 2004 e1 e8
120. M.E. Urick, E.J. Chung, W.P. Shield III, N. Gerber, A. White, and A. Sowers et al. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition Clin Cancer Res 17 2011 5038 5047
121. C.D. Van Raamsdonk, V. Bezrookove, G. Green, J. Bauer, L. Gaugler, and J.M. O'Brien et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi Nature 457 2009 599 602
122. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, and P. Pochanard et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 2011 3085 3096
123. H. Wang, S. Daouti, W.H. Li, Y. Wen, C. Rizzo, and B. Higgins et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation Cancer Res 71 2011 5535 5545
124. S. Wee, Z. Jagani, K.X. Xiang, A. Loo, M. Dorsch, and Y.M. Yao et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res 69 2009 4286 4293
125. T.M. Williams, A.R. Flecha, P. Keller, A. Ram, D. Karnak, and S. Galban et al. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer Mol Cancer Ther 11 2012 1193 1202
126. T.R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, and E. Chan et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 487 2012 505 509
127. J. Xu, J.J. Knox, E. Ibrahimov, E. Chen, S. Serra, and M. Tsao et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer Clin Cancer Res 19 2013 118 127
128. J.J. Yeh, E.D. Routh, T. Rubinas, J. Peacock, T.D. Martin, and X.J. Shen et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer Mol Cancer Ther 8 2009 834 843
129. C. Yun, H. Cho, S.J. Kim, J.H. Lee, S.Y. Park, and G.K. Chan et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway Mol Cancer Res 2 2004 159 169
130. M. Zhang, Q. Ma, H. Hu, D. Zhang, J. Li, and G. Ma et al. Stem cell factor/c-kit signaling enhances invasion of pancreatic cancer cells via HIF-1alpha under normoxic condition Cancer Lett 303 2011 108 117